A pharmaceutical company is executing a predictive project to build a new quality control laboratory, scheduled for completion in 14 months. Six months into execution, a competitor announces a breakthrough product that significantly changes market dynamics. The executive team convenes an emergency strategy session and decides to pivot the company's product portfolio, which will require different laboratory specifications and testing capabilities than originally planned. The current project is 40% complete with $3.2M spent of the $7M budget. Preliminary analysis suggests retrofitting the in-progress facility would cost $2.1M additional, while stopping and redesigning would cost $1.8M but delay completion by 5 months. What should the project manager recommend?

Question

Accepted Answer

The correct answer is B. When external market changes trigger strategic pivots during project execution, decision-making requires analysis beyond simple cost comparison. The project manager must evaluate total cost of ownership (including operational costs of a suboptimal facility), time-to-market value in the new competitive landscape, opportunity costs of delays, and strategic fit with the revised business direction. The 5-month delay versus $300K savings trade-off cannot be properly evaluated without understanding the business value of earlier market entry with the new product portfolio. Option C jumps to a conclusion based solely on upfront cost without considering the strategic implications of delayed capability deployment or long-term operational impacts. While C appears data-driven, it oversimplifies a complex business decision. Options A and D represent extreme positions that either ignore the strategic shift or create analysis paralysis. The hard difficulty lies in recognizing that cost data alone is insufficient for strategic project decisions.

PMP Practice Question: Business Environment — Predictive, Hard

More Business Environment Questions